Ibudilast for the treatment of multiple sclerosis

References

• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(Pt 3):393–399.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. New England J Med. 1998;338(5):278–285.
   PubMed Web of Science ®Google Scholar
• Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol. 1993;52:199–204.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol [Internet]. 1993;33(2):137. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8434875.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol [Internet]. 1979;5(1):22–31. Available from: http://onlinelibrary.wiley.com/doi/10.1002/ana.410050105/abstract.
   PubMed Web of Science ®Google Scholar
• Chang A, Tourtellotte WW, Rudick R, et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. New England J Med. 2002;346(3):165–173.
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996;6(3):259–274.
   PubMed Web of Science ®Google Scholar
• Sobel RA, Moore GRW. Demyelinating diseases. In: Love S, Louis DN, Ellison DW, editor. Greenfield’s neuropathology. New York: Oxford Univ. Press; 2008. p. 1513–1608.
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. New England J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet. 2011;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1–2):63–70.
   PubMed Web of Science ®Google Scholar
• Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092–6099.
   PubMed Web of Science ®Google Scholar
• Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166.
   PubMed Web of Science ®Google Scholar
• Piccio L, Naismith R, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67:707–714
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell–mediated disease in MS? Ann Neurol. 2010;67(4):452–461.
   PubMed Web of Science ®Google Scholar
• Imam SA, Guyton MK, Haque A, et al. Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol. 2007;190(1):139–145.
   PubMed Web of Science ®Google Scholar
• Compston A, McDonald IR, Noseworthy J, et al.. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone; 1998.
   Google Scholar
• Witte ME, Nijland PG, Drexhage JA, et al. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol. 2013;125:231–243.
   PubMed Web of Science ®Google Scholar
• Hochmeister S, Grundtner R, Bauer J, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 2006;65:855–865.
   PubMed Web of Science ®Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–1189.
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705–2712.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanism in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–193.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002;1(4):232–241.
   PubMed Web of Science ®Google Scholar
• Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2011;69:481–492.
   PubMed Web of Science ®Google Scholar
• Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59(3):478–489.
   PubMed Web of Science ®Google Scholar
• Witte ME, Mahad DJ, Lassmann H, et al. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med. 2014;20(3):179–187.
   PubMed Web of Science ®Google Scholar
• Goldschmidt T, Antel J, Konig FB, et al. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology. 2009;72:1914–1921.
   PubMed Web of Science ®Google Scholar
• Fischer MT, Wimmer I, Hoftberger R, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain. 2013;136:1799–1815.
   PubMed Web of Science ®Google Scholar
• English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37(4):691–715.
   PubMed Web of Science ®Google Scholar
• Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418–1428.
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2014;(5). Article No. CD002127.
   Google Scholar
• Nicholas J, Morgan-Followell B, Pitt D, et al. New and emerging disease-modifying therapies for relapsing-remitting multiple sclerosis: what is new and what is to come. J Cent Nerv Syst Dis. 2012;4:81–103.
   PubMedGoogle Scholar
• Kawasaki A, Hoshino K, Osaki R, et al. Effect of ibudilast: a novel anti-asthmatic agent, on airway hyper-sensitivity in bronchial asthma. J Asthma. 1992;29:245–252.
   PubMed Web of Science ®Google Scholar
• Gibson LCD, Hastings SF, McPhee I, et al. The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol. 2006;538(1):39–42.
   PubMed Web of Science ®Google Scholar
• Vang T, Torgersen KM, Sundvold V, et al. Activation of the cooh-terminal Src Kinase (Csk) by camp-dependent protein kinase inhibits signaling through the T cell receptor. Exp Med. 2001;193(4):497–508.
   PubMed Web of Science ®Google Scholar
• Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991;146(1):108–113.
   PubMed Web of Science ®Google Scholar
• Kishi Y, Ohta S, Kasuya N, et al. Ibudilast modulates platelet-endothelium interaction mainly through cyclic GMP-dependent mechanism. J Cardiovasc Pharmacol. 2000;36(1):65–70.
   PubMed Web of Science ®Google Scholar
• Kishi Y, Ohta S, Kasuya N, et al. Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc Drug Rev. 2001;19(3):215–225.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Kurotani T, Komatsu Y, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46(3):404–411.
   PubMed Web of Science ®Google Scholar
• Suzumura A, Ito A, Yoshikawa M, et al. Ibudilast suppresses TNFα production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999;837(1–2):203–212.
   PubMed Web of Science ®Google Scholar
• Suzumura A, Ito A, Mizuno T. Phosphodiesterase inhibitors suppress IL-12 production with microglia and T helper 1 development. Mult Scler. 2003;9(6):574–578.
   PubMed Web of Science ®Google Scholar
• Kiebala M, Maggirwar S. Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells. PLOSOne. 2011;6(4):1–13.
   Web of Science ®Google Scholar
• Takuma K, Lee E, Enomoto R, et al. Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol. 2001;133(6):841–848.
   PubMed Web of Science ®Google Scholar
• Wakita H, Tomimoto H, Akiguchi I, et al. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. 2003;992(1):53–59.
   PubMed Web of Science ®Google Scholar
• Lilius TO, Rauhala PV, Kambur O, et al. Modulation of morphine-induced antinociception in acute and chronic opioid treatment by ibudilast. Anesthesiology. 2009;111(6):1356–1364.
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Lewis SS, Coats BD, et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun. 2009;23(2):240–250.
   PubMed Web of Science ®Google Scholar
• Ibudilast in the treatment of patients with chronic migraine, NCT01389193. National Institutes of Health, ClinicalTrials.gov; updated 2015 May 12; cited 2016 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT01389193?term=ibudilast&rank=2.
   Google Scholar
• Effects of ibudilast on oxycodone self-administration in opioid abusers, NCT01740414. National Institutes of Health, ClinicalTrials.gov; updated 2015 Aug 31; cited 2016 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT01740414?term=ibudilast&rank=7.
   Google Scholar
• Aversa TGD, Yu KO, Berman JW. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein tat. J Neurovirol. 2004;10(2):86–97.
   PubMed Web of Science ®Google Scholar
• Byrd DA, Fellows RP, Morgello S, et al. Neurocognitive impact of substance use in HIV infection. JAIDS J Acquir Immune Defic Syndr. 2011;58(2):154–162.
   PubMed Web of Science ®Google Scholar
• Hauser K, Fitting S, Dever S, et al. Opiate drug use and the pathophysiology of NeuroAIDS. Curr HIV Res. 2012;10(5):435–452.
   PubMed Web of Science ®Google Scholar
• El-Hage N, Rodriguez M, Podhaizer E, et al. Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine. Aids. 2014;28(10):1409–1419.
   PubMed Web of Science ®Google Scholar
• Rolan P, Gibbons JA, He L, et al. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol. 2008;66:792–801.
   PubMed Web of Science ®Google Scholar
• Sanftner LM, Gibbons JA, Gross MI, et al. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica. 2009;39(12):964–977.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Sakoda S, Fujimura H, et al. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in dark august rats. J Neuroimmunol. 1999;95(1):35–42.
   PubMed Web of Science ®Google Scholar
• Misu T, Onodera H, Fujihara K, et al. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol. 2001;114(1–2):207–212.
   PubMed Web of Science ®Google Scholar
• Feng J, Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler. 2004;10(5):494–498.
   PubMed Web of Science ®Google Scholar
• Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74(13):1033–1040.
   PubMed Web of Science ®Google Scholar
• Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009;10(17):2897–2904.
   PubMed Web of Science ®Google Scholar
• SPRINT-MS: “A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and activity of ibudilast (MN-166) in subjects with progressive multiple sclerosis”. NIH-NeuroNext;. Available from: https://www.neuronext.org/nn102-sprint-ms.
   Google Scholar
• Safety, tolerability and activity study of ibudilast in subjects with progressive multiple sclerosis, NCT01982942. National Institutes of Health, ClinicalTrials.gov; [updated 2015 May 12; cited 2016 Jan 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT01982942?term=ibudilast+and+multiple+sclerosis&rank=1.
   Google Scholar